Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

by Medical Finance
in Coronavirus
Study: Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Image Credit: joshimerbin/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the medRxiv* preprint server, researchers tested the efficacy of sotrovimab, a neutralizing monoclonal antibody (mAb), in non-hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They reported how sotrovimab prevented progression to severe coronavirus disease 2019 (COVID-19) and associated hospitalizations and deaths.

Study: Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Image Credit: joshimerbin/Shutterstock
Study: Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Image Credit: joshimerbin/Shutterstock

Background

The United States (US) Food and Drug Administration (FDA) approved emergency use authorization (EUA) of several mAbs early in the pandemic. One such mAb, sotrovimab, demonstrated high efficacy in reducing hospitalization and progression to severe disease course among high-risk outpatients in trials conducted before the emergence of the SARS-CoV-2 Delta variant of concern (VOC).

Following EUA approval for sotrovimab, clinical trials assessing its clinical outcomes or mortality concerning coronavirus disease 2019 (COVID-19) were sparse. Also, enrolling patients in randomized controlled trials became more challenging. However, as of January 24th, 2022, sotrovimab is the only authorized mAb for outpatient COVID-19 treatment.

In such a scenario, and amid the emergence of new SARS-CoV-2 VOC Omicron, additional real-world data supporting the clinical effectiveness of sotrovimab is crucial for informing policy and clinical practice decisions.

About the study

In the present propensity-matched observational study conducted in Colorado, researchers enrolled 10,036 patients who contracted SARS-CoV-2 infection between October 1st, 2021, and December 11th, 2021, when the SARS-CoV-2 Delta VOC was predominant. They developed a novel real-world evidence platform to assess the clinical impact of sotrovimab therapy on high-risk symptomatic COVID-19 outpatients, followed up for a minimum of 28 days.

The researchers obtained the study data from the electronic health record (EHR) of UCHealth, the largest health system in Colorado, and merged this data with statewide data on vaccination status and COVID-19 mortality from the Colorado comprehensive immunization information system and Colorado vital records, respectively.

EHR data confirmed the patient’s first SARS-CoV-2 positive test date (or the date of start of mAb therapy). The team randomly imputed missing test dates using the normally observed time between SARS-CoV-2 infection to mAb administration.

The researchers performed nearest neighbor propensity matching using logistic regression with treatment status as the outcome, which matched 1,563 untreated patients with 522 sotrovimab-treated patients, i.e., in a ratio of 3:1.

The propensity model accounted for gender, age, ethnicity, race,  immunocompromised status, obesity and other comorbid conditions, vaccine doses at the time of infection (zero, one, two, three), and insurance status. Lastly, they assessed the effectiveness of matching using standardized mean differences (SMDs) with a threshold of 0.1.

The primary outcome of the study was hospitalization within 28 days of a positive SARS-CoV-2 test, and there were several secondary outcomes – 28-day all-cause mortality, in-hospital mortality, emergency department (ED) visit within 28 days, and intensive care unit (ICU) length of stay (LOS). Notably, the researchers considered the index visit for hospitalization and ED visits during the analysis.

The researchers used Kaplan-Meier curves to assess the cumulative incidence patterns by treatment status for 28-day hospitalization and also performed two sensitivity analyses.

Study findings

Sotrovimab-treated COVID-19 outpatients showed a much-lower hospitalization rate in comparison to mAb-untreated controls during the Delta variant phase (2.1% vs. 5.7%); accordingly, the authors noted a 63% decrease in the adjusted odds ratio (aOR) of hospitalization, reinforcing the efficacy of sotrovimab treatment. Interestingly, vaccination also decreased the odds of hospitalization, with a more pronounced decrease observed with an increase in vaccine doses.

Sotrovimab therapy reduced mortality odds by 89% in 28 days (aOR:0.11); however, it did not change the odds of visiting the ED (aOR:1.12). The unadjusted number needed to treat (NNT) of 28 to prevent one hospitalization for the untreated group further supported sotrovimab effectiveness against Delta VOC.

A time-to-event analysis revealed that the benefits of sotrovimab therapy accrued on an average of nine days of treatment. Importantly, sensitivity analyses did not alter the results and scientific conclusions of the current study.

Conclusions

Based on the study findings, the authors recommended continued clinical use of sotrovimab, especially for patients with a high baseline risk for hospitalization. Additionally, sotrovimab could prevent the progression to severe COVID-19 and subsequent hospitalization among the elderly (over 65 years), obese, partially vaccinated, unvaccinated, or individuals with comorbid conditions, such as hypertension and pulmonary disease. Furthermore, the study findings could guide the decision-making of policymakers and clinicians amid shortages of mAb supplies and infusion capacity.

In vitro studies suggest that sotrovimab could also effectively neutralize Omicron because it targets non-receptor-binding motif (RBM) epitopes conserved across many sarbecoviruses. However, future studies should examine sotrovimab effectiveness against Omicron in real-world settings to reaffirm the in vitro findings.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Protection by vaccines and previous infection against 2 the Omicron variant of SARS-CoV-2. Image Credit: CROCOTHERY/Shutterstock

How protection due to vaccination or previous SARS-CoV-2 infection varies for the population of the Czech Republic

by Medical Finance
May 19, 2022
0

The emergence of Omicron, the most recent variant of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...

Study: Risk factors for severe COVID-19 differ by age for hospitalized adults. Image Credit: GEMINI PRO STUDIO/Shutterstock

High-performing age-stratified machine-learning models for the prediction of the severity of COVID-19 progression

by Medical Finance
May 19, 2022
0

Hundreds of millions of cases of coronavirus disease 2019 (COVID-19) have been documented over the last two years during the...

Study: Persistent symptoms after SARS-CoV-2 infection: Long-term implications for health and quality of life. Image Credit: Dragana Gordic / Shutterstock.com

What are the long-term symptoms of SARS-CoV-2 infection?

by Medical Finance
May 19, 2022
0

Recent studies have suggested that people who have recovered from the coronavirus disease 2019 (COVID-19) are at increased risk of...

Study: Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study. Image Credit: M-Foto/Shutterstock

Effectiveness of COVID-19 vaccines against hospitalization in those testing positive for Omicron and Delta variants

by Medical Finance
May 19, 2022
0

A recent study posted to the medRxiv* preprint server assessed the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: Detection of SARS-CoV-2 infection by microRNA profiling of the upper respiratory tract. Image Credit: Nhemz/Shutterstock

Exploring SARS-CoV-2 detection by profiling micro RNAs

by Medical Finance
May 19, 2022
0

In a recent study published in PLOS ONE, researchers analyzed the micro ribonucleic acid (miRNA) profiles in nasal swabs collected...

Phico Therapeutics establishes Scientific Advisory Board

ECG can pinpoint hospitalized COVID-19 patients at high risk of mortality

by Medical Finance
May 19, 2022
0

A simple electrocardiogram (ECG) can pinpoint hospitalized COVID-19 patients at high risk of death who might need intensive management. That's...

Next Post
Study: A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface. Image Credit: MIA Studio/Shutterstock

Researchers investigate SARS-CoV-2 specific inflammatory response

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • 174318220 620x480
    Researchers find a way to interfere with the energy pathway that promotes liver cancer spread
  • Study: Genomic monitoring unveils a high prevalence of SARS-CoV 2 Omicron Variant in vaccine breakthrough cases in Bahia, Brazil. Image Credit: haidaralf/Shutterstock
    SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply